Emergent BioSolutions To Sell Baltimore-Camden Manufacturing Site To Bora Pharma For $30M
Portfolio Pulse from Benzinga Newsdesk
Emergent BioSolutions Inc. (NYSE:EBS) has agreed to sell its Baltimore-Camden manufacturing site to Bora Pharmaceuticals for $30 million. The site includes non-viral aseptic fill/finish services and approximately 350 employees will transfer to Bora.
June 20, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Emergent BioSolutions Inc. (NYSE:EBS) is selling its Baltimore-Camden manufacturing site to Bora Pharmaceuticals for $30 million. This move includes the transfer of 350 employees to Bora.
The sale of the Baltimore-Camden site for $30 million will provide Emergent BioSolutions with additional capital and reduce operational costs. The transfer of 350 employees to Bora will also streamline Emergent's workforce, potentially improving its financial position in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100